tirzepatide protein intake optimization research Investigating nutrient during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study Optimizing Nutrition and Protein on

Cell 75 (1), 5972

Answer: Semaglutide is a GLP-1 receptor agonist, a prescription medication originally developed for type 2 diabetes and now FDA-approved for chronic weight management, given as a once-weekly injection that reduces appetite and slows digestion

This makes it not only a medication for managing diabetes and weight but also a potential protector of overall heart health

Others leave health care altogether

The FDA prescribing information for semaglutide and tirzepatide lists nausea, vomiting, diarrhea, constipation, and abdominal pain as frequent adverse reactions

Basic liver testing can detect acquired problems that reduce FMO3 activity